✦ LIBER ✦

132 A phase I and pharmacokinetic clinical trial of subcutaneous (sc) VEGF trap in advanced solid tumor patients

✍ Scribed by J. Dupont; L. Schwartz; J. Koutcher; D.R. Spriggs; M.S. Gordon; D. Mendelson; J. Murren; A. Lucarelli; J.M. Cedarbaum

Book ID: 118621317
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 144 KB
Volume: 2
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(04)80140-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of subcutaneously admini

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

✍ Andrea Wang-Gillam, William P. Tew, Mace L. Rothenberg, Jakob Dupont, Wendy Coop 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 127 KB

A phase I trial and pharmacokinetic eval

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors

✍ Nancy T. Sklarin; Chetan D. Lathia; Laura Benson; Williamn R. Grove; Sylvia Thom 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 88 KB

A phase I pharmacokinetics study of 9-ni

A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors

✍ Zhao Yan; Zhongling Zhu; Kai Li; Peng Chen; Liuchun Wang; Chun Huang; Jinhuai Xu 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 209 KB

A phase I trial of perillyl alcohol in p

A phase I trial of perillyl alcohol in patients with advanced solid tumors

✍ Christopher G. Azzoli; Vincent A. Miller; Kenneth K. Ng; Lee M. Krug; David R. S 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 232 KB

Pharmacokinetic results of a phase I tri

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

✍ Erich Brendel; Matthias Ludwig; Chetan Lathia; Caroline Robert; Stanislas Ropert 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 367 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi